ANDOVER, Mass., Aug. 01, 2017 -- MKS Instruments, Inc. (NASDAQ:MKSI), a global provider of technologies that enable advanced processes and improve productivity, today announced that its board of directors has authorized a quarterly cash dividend of $0.175 per share, payable on September 8, 2017 to shareholders of record as of August 28, 2017.
Future dividend declarations, as well as the record and payment dates for such dividends, are subject to the final determination of the company's Board of Directors.
About MKS Instruments
MKS Instruments, Inc. is a global provider of instruments, subsystems and process control solutions that measure, control, power, monitor, and analyze critical parameters of advanced manufacturing processes to improve process performance and productivity. Our products are derived from our core competencies in pressure measurement and control, flow measurement and control, gas and vapor delivery, gas composition analysis, residual gas analysis, leak detection, control technology, ozone generation and delivery, RF & DC power, reactive gas generation, vacuum technology, lasers, photonics, sub-micron positioning, vibration isolation, and optics. Our primary served markets include semiconductor capital equipment, general industrial, life sciences, and research. Additional information can be found at www.mksinst.com.
Forward-Looking Statements
This release contains projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27 of the Securities Act, and Section 21E of the Securities Exchange Act regarding MKS' future growth and the future financial performance of MKS. These projections or statements are only predictions. Actual events or results may differ materially from those in the projections or other forward-looking statements set forth herein. Readers are referred to MKS' filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for a discussion of these and other important risk factors concerning MKS and its operations. MKS is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact: Seth Bagshaw Senior Vice President and Chief Financial Officer Telephone: 978.645.5578 Email: [email protected] Investor Relations Contact: Monica Gould The Blueshirt Group Telephone: 212.871.3927 Email: [email protected] Lindsay Savarese The Blueshirt Group Telephone: 212-331-8417 Email: [email protected]


U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 



